StockWatch
·
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Quarterly ResultOct 6, 2026, 04:07 PM

Neogen Q1 FY27 Revenue $222.8M (+6.5%); Raises FY27 Guidance

AI Summary

Neogen Corporation announced its first-quarter financial results for fiscal year 2027, reporting a 6.5% increase in revenue to $222.8 million, with core revenue growth of 8.1%. The company posted a net loss of $11.9 million, or $(0.05) per share, compared to a net income of $36.3 million in the prior year, primarily due to a gain on divestiture in the previous period. However, Adjusted Net Income was $17.5 million, or $0.08 per share. Neogen is raising its fiscal year 2027 financial guidance for both revenue and Adjusted EBITDA, reflecting positive operational momentum and strategic initiatives including a collaboration with Hinalea Imaging Corp.

Key Highlights

  • Neogen reports Q1 FY27 revenue of $222.8M, up 6.5% YoY; core revenue grew 8.1%.
  • Food Safety revenue increased 7.4% to $163.2M; Animal Safety revenue grew 4.2% to $59.6M.
  • Q1 FY27 net loss of $11.9M ($0.05 EPS); Adjusted Net Income $17.5M ($0.08 EPS).
  • Adjusted EBITDA was $41.6M, up from $35.5M YoY, with margin at 18.7%.
  • Cash flow from operations was $12.9M; free cash flow was $4.7M.
  • Company is on track for Petrifilm manufacturing transition in November 2026.
  • Neogen is raising FY27 revenue and Adjusted EBITDA guidance.
  • Announced strategic collaboration and equity investment in Hinalea Imaging Corp.